Moderna is building a broad portfolio of vaccines while advancing a late-stage clinical pipeline. The company plans to grow its seasonal vaccine offering from three approved products today to as many as six by 2028. Management projects that total revenue will rise 10 % in 2026. Cash generated from existing vaccine products is earmarked for investment in oncology and rare disease programs, laying the groundwork for further growth in 2027 and 2028. Early-stage pipeline investments are expected to begin maturing in 2029 and beyond. Access to newly secured credit strengthens the firm’s liquidity to support these initiatives.

Total raised

$3.5B

Funding rounds

7

Latest round

Equity

Latest activity

Feb 2018